A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan

Caio Max Rocha-Lima, Eriberto De Queiroz Marques, Soley Bayraktar, Paul Broome, Charles Weissman, Marek Nowacki, Martin Leslie, Shabbir Susnerwala

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Background: The G17DT is a novel human immunogen that raises antibodies to the growth factor gastrin 17 (G17). The purpose of this study was to determine the safety and efficacy of G17DT in combination with irinotecan in patients refractory to irinotecan, and to correlate efficacy with anti-G17 immune response. Methods: Patients received G17DT immunogen as a single intramuscular injection of 500 μg at weeks 1, 5, 9, and 26. Irinotecan was administered as an intravenous infusion of 125 mg/m2 over 90 min starting at week 5. Each cycle of treatment consisted of irinotecan administered once weekly for 4 weeks, followed by a 2-week rest period. Results: Of 161 patients who received G17DT, the best overall tumor response in the intent-to-treat population was complete response 0 (0 %), partial response 3 (3 %), stable disease 32 (32 %), and progressive disease 64 (65 %). Median survival was 217 days. About 94 (62 %) subjects evaluable for antibody titers were anti-G17 responders. Survival was significantly longer for anti-G17 responders compared with non-responders (9.0 vs. 5.6 months; P < 0.001). Toxicity was consistent with irinotecan (diarrhea, nausea, anemia, vomiting, fatigue, constipation, anorexia, and neutropenia) except for injection site reactions (pain 42 %, induration 13 %, edema 11 %, erythema 10 %, and three abscesses) attributed to G17DT in 52 % of the patients. Conclusion: Treatment with G17DT in combination with irinotecan results in an acceptable anti-G17 immune response, which correlated with promising survival activity in patients refractory to irinotecan-based chemotherapy.

Original languageEnglish (US)
Pages (from-to)479-486
Number of pages8
JournalCancer Chemotherapy And Pharmacology
Volume74
Issue number3
DOIs
StatePublished - Sep 2014

Keywords

  • G17DT
  • Immunotherapy
  • Irinotecan
  • Irinotecan refractory
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Fingerprint Dive into the research topics of 'A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan'. Together they form a unique fingerprint.

  • Cite this

    Rocha-Lima, C. M., De Queiroz Marques, E., Bayraktar, S., Broome, P., Weissman, C., Nowacki, M., Leslie, M., & Susnerwala, S. (2014). A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan. Cancer Chemotherapy And Pharmacology, 74(3), 479-486. https://doi.org/10.1007/s00280-014-2520-y